Sub-millimetric, patient-specific brain targeting for functional neurosurgery and real-world outcomes in Parkinson’s Disease and Essential Tremor.

ActuIA Features RebrAIn’s Innovations in Supervised AI-Driven Deep Brain Stimulation

We are excited to share that RebrAIn has been featured by ActuIA for our innovative work in neurosurgical targeting for Deep Brain Stimulation (DBS).

The article highlights our supervised AI-driven solutions that significantly improve patient outcomes for those with Parkinson’s Disease and Essential Tremor. Founded by Professor Emmanuel Cuny and Dr. Nejib Zemzemi, RebrAIn is transforming the landscape of neurosurgery with our precise and effective treatments.

Read the full article, “Focus on RebrAIn, the start-up that aims to revolutionize the surgical targeting of Deep Brain Stimulation”, in French on actuia.com here.

An English translation by Google is available here.

Our latest public updates

RebrAin 2025/2026: Expanding Reach, Driving Innovation

RebrAin 2025/2026: Expanding Reach, Driving Innovation

Jan 5, 2026

Transatlantic expansion RebrAIn’s focus for 2026 is expanding our reach to major neurosurgery reference centers in the US and Europe. Today, our top partner centers by volume are Duke University, University of Virginia (UVA), Pamplona and UCLA. These collaborations...

Rebrain publishes OPTIVIM trial results in Neurosurgery

Rebrain publishes OPTIVIM trial results in Neurosurgery

Dec 5, 2025

An innovative and automated method RebrAIn’s service is based on a machine learning model trained on data from successfully treated patients. Using only a standard 3D T1 MRI, the algorithm automatically computes the stereotactic coordinates of the optimal DBS target,...